PMID: 8938029Nov 1, 1996Paper

Physical aspects of total-body irradiation at the Middlesex Hospital (UCL group of hospitals), London 1988-1993: II. In vivo planning and dosimetry

Physics in Medicine and Biology
B PlanskoyF M Davis

Abstract

Part II of this paper gives the results of applying the TBI methods described in part I, to in vivo patient planning and dosimetry. Patients are planned on nine CT based body slices, five of which pass through the lungs. Planned doses are verified with ten silicon diodes applied bi-laterally to five body sites, at each treatment. LiF TLDs are applied to seven other body sites at the first treatment only. For 84 patients and at least 1016 measurements per body site with the diodes, the mean measured total doses agreed with planned doses within at most 2% except at lung levels, where the mean measured dose was 3% too low. Standard deviations of the measurements about the mean were between 2.4 and 3.1%. For the LiF TLDs, the mean measured doses for all seven body sites were with in +/- 5% of planned doses. A separate assessment of measured entrance and transmitted doses showed that the former agreed well with planned doses, but that the latter tended to be low, especially over the lungs, and that they had a wider dispersion. Possible reasons for this are discussed. These results show measurement uncertainties similar to those for non-TBI treatments of Nilsson et al, Leunens et al and Essers et al. An analysis of the treatment plan...Continue Reading

References

Jan 1, 1991·Physics in Medicine and Biology·S HeukelomB J Mijnheer
Jan 1, 1990·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·E BriotA Bridier
Sep 1, 1990·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·G LeunensE van der Schueren
Mar 1, 1988·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·B NilssonB Sorcini
Jun 1, 1987·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·U Quast
Aug 1, 1982·International Journal of Radiation Oncology, Biology, Physics·J Van DykW D Rider
Nov 1, 1980·Radiology·L J RosenblumE R Heitzman
Dec 1, 1995·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·M EssersB J Mijnheer

❮ Previous
Next ❯

Citations

Oct 25, 2008·Australasian Physical & Engineering Sciences in Medicine·C M LancasterS R Davis
Feb 3, 2012·Australasian Physical & Engineering Sciences in Medicine·P R Satory
Jun 28, 2000·Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology·C FiorinoR Calandrino
Aug 27, 1998·International Journal of Radiation Oncology, Biology, Physics·J A Kalef-EzraP Tsekeris
Feb 25, 1999·International Journal of Radiation Oncology, Biology, Physics·M Essers, B J Mijnheer
Aug 26, 2014·Medical Dosimetry : Official Journal of the American Association of Medical Dosimetrists·David J EatonChristopher H Collis
Sep 16, 2009·The British Journal of Radiology·C R Edwards, P J Mountford
Jan 31, 2012·International Journal of Radiation Oncology, Biology, Physics·Cem OnalEzgi Oymak
Sep 11, 2014·Journal of Applied Clinical Medical Physics·Reshma P PatelIvan Rosenberg
Mar 2, 2005·Journal of Applied Clinical Medical Physics·Susanta K HuiDouglas Henderson
Dec 29, 2018·Journal of Applied Clinical Medical Physics·Greg PierceAlana Hudson

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
P MangiliR Calandrino
International Journal of Cancer. Journal International Du Cancer
A KassaeeB E Bjärngard
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
M RibasF Sánchez-Doblado
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
E BriotA Bridier
© 2021 Meta ULC. All rights reserved